Trial Profile
Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
- Focus Adverse reactions
- 16 Jul 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2019 Planned End Date changed from 1 Nov 2015 to 12 Jan 2020.